This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.

BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.

Eyconis Announces First Patients Dosed In Phase 1b/2a OVERTURE Trial Of EYC-0305 In Treatment-Naïve Wet AMD Patients, Using TransCon Technology Licensed From Ascendis Pharma

DigitalOcean Holdings shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a $175 price target.

Truist Securities Initiates Coverage On DigitalOcean Holdings with Buy Rating, Announces Price Target of $175

Truist Securities analyst Miller Jump initiates coverage on DigitalOcean Holdings (NYSE:DOCN) with a Buy rating and announces Price Target of $175.

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.